In agreement with prior meta-analyses [13,14] this meta-analysis demonstrated the significant improvement of glycemic control in patients with type 2 diabetes treated with SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.